MetLife Lags Peers as Analysts Keep Raising Targets

MetLife trails its life insurance peer group this week, gaining just 0.5% while the median of its closest comparables rose 1.6%. FNF added 3.2% and PRI 2.6%, while AIG led the group with a 5.4% advance. Only LNC fared worse, slipping 2.7%. At $101.18, MetLife is up 4.3% on the month, but the relative underperformance this week stands out given how uniformly bullish the Street has become on the name.

Analyst conviction has rarely been this one-directional. Every firm that has touched the stock in the past three weeks has either raised its target or upgraded its rating outright. TD Cowen lifted its target to $114 today, from $110. JPMorgan moved to $110 from $108 last week. Wells Fargo, Barclays, and UBS all raised targets in early October. The mean price target now sits at $107.38, roughly 6% above the current price, and the forward EPS revision factor ranks in the 94th percentile. Piper Sandler flipped from Neutral to Overweight in late September, completing what amounts to a clean sweep of positive sentiment from the Street. The only dissent in the recent run came from Mizuho, which trimmed its target from $112 to $109 on October 7 while keeping an Outperform rating. That lone cut reads more like housekeeping than conviction.

Where analysts are firm, short sellers have been retreating. Short interest has fallen roughly 8% over the past month to 1.7% of the free float, a level too low to generate meaningful squeeze mechanics. The borrow market is the same story: cost to borrow is just 0.37%, down 16% on the week, and availability is effectively unconstrained. With nearly 489 million shares available to borrow and short interest sitting at around 11.3 million, the lending pool dwarfs the short position many times over. This is not a market where bears are pressing a thesis aggressively.

Options positioning complicates the picture slightly. The put/call ratio has moved above its recent average, running at 1.58 against a 20-day mean of 1.48. That puts it about 1.4 standard deviations above the norm, closer to the defensive end of its one-year range of 1.07 to 1.81. The elevated put demand may reflect hedging ahead of Q3 results, due November 4, rather than outright bearishness. MET's last two earnings prints produced modest positive moves, with a roughly 2% gain the day after Q2 and a smaller 1.6% day-one move before the week gave back some of that. The pattern is not one of explosive reactions, which makes heavy hedging somewhat at odds with recent history.

The activist register carries one item worth noting. The MetLife Policyholder Trust, which filed a Schedule 13D with the SEC, holds 16.1% of the company, down slightly from 16.2% at the prior disclosure. The 13D flag indicates the position is classified as activist under SEC rules, though the Trust's nature as a policyholder vehicle makes this a structural holding rather than a conventional campaign. BlackRock added 1.6 million shares in the most recent quarter to reach 8.1% of shares. T. Rowe Price and Dimensional Fund Advisors also added modestly. Retail attention, as measured by Wikipedia pageviews, has moved about 1.8 standard deviations above MetLife's own 90-day average, an attention signal without direct earnings implications.

The number that would shift the picture for the coming two weeks is whether the stock can close the gap to the $107 to $114 range where the analyst consensus clusters. With Q3 results on November 4, whether MetLife's relative underperformance against peers this week reflects a deliberate wait-and-see posture or something more structural is what that print will answer.